Defense Health Agency Contracting Activity - DHACA Grants

Defense Health Agency Contracting Activity - DHACA

<p>Summary: This funding mechanism supports interventional research at the individual and/or health care system level which will result in near-term impact on the health-related quality of life of individuals living with lupus. The emphasis is on near-term impact on quality of life. Research must address at least one of the fiscal year 2026 (FY26) Lupus Research Program (LRP) Transformative Vision Award (TVA) focus areas. This mechanism allows for clinical trials but does not allow animal studies.</p><p><br></p><p>Distinctive Features:</p><p>• Applications must include preliminary data.</p><p>• Applications must include at least one lupus consumer advocate as a member of the research team.</p><p>• This funding mechanism allows for up to three Principal Investigators (PIs). Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI(s) application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application(s) is rejected or administratively withdrawn.</p><p>• An individual may be named as PI on only one application per LRP award mechanism (Idea Award, Impact Award, Transformative Vision Development Award, TVA), for a maximum of four applications to the FY26 LRP.</p>

Defense Health Agency Contracting Activity - DHACA

Summary: This funding mechanism supports high-risk/high-reward research that has the potential to make a major impact in lupus research and/or lupus disease. The emphasis is on impact. Research must address at least one of the fiscal year 2026 (FY26) Lupus Research Program (LRP) Impact Award (IPA) focus areas. This funding mechanism does not allow clinical trials.Distinctive Features: The FY26 LRP IPA encourages, but does not require, preliminary data.An individual may be named as Principal Investigator (PI) on only one application per LRP award mechanism (Idea Award, IPA, Transformative Vision Development Award, Transformative Vision Award), for a maximum of four applications to the FY26 LRP.

Defense Health Agency Contracting Activity - DHACA

Summary: This funding mechanism supports interventional research at the individual and/or health care system level which will result in near-term impact on the health-related quality of life of individuals living with lupus. The emphasis is on near-term impact on quality of life. Research must address at least one of the fiscal year 2026 (FY26) Lupus Research Program (LRP) Transformative Vision Award (TVA) focus areas. This mechanism allows for clinical trials but does not allow animal studies.Distinctive Features: Applications must include preliminary data. Applications must include at least one lupus consumer advocate as a member of the research team. This funding mechanism allows for up to three Principal Investigators (PIs). Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI(s) application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application(s) is rejected or administratively withdrawn. An individual may be named as PI on only one application per LRP award mechanism (Idea Award, Impact Award, Transformative Vision Development Award, TVA), for a maximum of four applications to the FY26 LRP.

Defense Health Agency Contracting Activity - DHACA

Summary: This funding mechanism supports innovative, high-risk/high-reward research that could ultimately lead to a critical discovery or major advancement relevant to lupus. The emphasis is on innovation. Research must address at least one of the fiscal year 2026 (FY26) Lupus Research Program (LRP) Idea Award (IA) focus areas. This funding mechanism does not allow clinical trials.Distinctive Features: Early-career investigators are eligible to serve as Principal Investigators (PIs) on applications to the FY26 LRP Idea Award (see Section 2. Eligibility Information). Preliminary data are permitted but not required. Applications should describe future directions of the work. An individual may be named as PI on only one application per LRP award mechanism (IA, Impact Award, Transformative Vision Development Award, Transformative Vision Award), for a maximum of four applications to the FY26 LRP

Defense Health Agency Contracting Activity - DHACA

<p>Summary: This funding mechanism supports planning and development activities and pilot studies that will generate preliminary data and demonstrate feasibility for achieving the aims of a future interventional study. Successful studies may be submitted to a future Lupus Research Program (LRP) Transformative Vision Award (TVA), or equivalent, for funding consideration (See Funding Opportunity Number HT942526LRPTVA for additional information). Research must address at least one of the fiscal year 2026 (FY26) LRP Transformative Vision Development Award (TVDA) focus areas. This funding mechanism allows for phase 0/1 clinical trials, if appropriate. The mechanism does not allow for phase 2/3 clinical trials or animal studies.</p><p><br></p><p>Distinctive Features:</p><p>• Preliminary data are permitted but not required.</p><p>• Applications must include at least one lupus consumer advocate as a member of the research team.</p><p>• An individual may be named as Principal Investigator (PI) on only one application per LRP award mechanism (Idea Award, Impact Award, TVDA, TVA), for a maximum of four applications to the FY26 LRP.</p>

Defense Health Agency Contracting Activity - DHACA

Summary: This funding mechanism supports planning and development activities and pilot studies that will generate preliminary data and demonstrate feasibility for achieving the aims of a future interventional study. Successful studies may be submitted to a future Lupus Research Program (LRP) Transformative Vision Award (TVA), or equivalent, for funding consideration (See Funding Opportunity Number HT942526LRPTVA for additional information). Research must address at least one of the fiscal year 2026 (FY26) LRP Transformative Vision Development Award (TVDA) focus areas. This funding mechanism allows for phase 0/1 clinical trials, if appropriate. The mechanism does not allow for phase 2/3 clinical trials or animal studies.Distinctive Features: Preliminary data are permitted but not required. Applications must include at least one lupus consumer advocate as a member of the research team. An individual may be named as Principal Investigator (PI) on only one application per LRP award mechanism (Idea Award, Impact Award, TVDA, TVA), for a maximum of four applications to the FY26 LRP.

Defense Health Agency Contracting Activity - DHACA

<p><strong>Summary:</strong> The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Data Science Award (DSA) supports research that develops or uses quantitative and analytical approaches, processes and/or systems to obtain knowledge and insight from large and/or complex sets of prostate cancer data in one or more of the following research areas: Analysis of clinically annotated datasets; analysis of -omics data; artificial intelligence and machine learning; bioinformatics; computational biology; digital pathology; epidemiology; and medical imaging. All applications must address one of the <a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/PCRP/HT942526PCRPDSA_for%20GO%20review.docx#Overarching_Challenges" target="_blank">FY26 PCRP Overarching Challenges</a>.</p> <p><br></p> <p><strong>Distinctive Features: This funding mechanism allows for multiple Principal Investigators (PIs).</strong> Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.</p> <p><br></p> <p><br></p>

Defense Health Agency Contracting Activity - DHACA

<p><strong>Summary:</strong> The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Physician Research Award (PRA) Supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research. All applications must address one of the <a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/PCRP/HT942526PCRPPRA_for%20GO%20review.docx#Overarching_Challenges" target="_blank">FY26 PCRP Overarching Challenges</a>.</p> <p><strong>Distinctive Features:</strong><strong style="color: red;"> </strong></p> <p><span style="color: black;">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><strong style="color: black;">Early-Career Clinician Investigator:</strong><span style="color: black;"> Serves as the Principal Investigator (PI). Includes investigators with clinical duties in the last year of an accredited medical residency or medical fellowship program, or within five years of initiating a faculty appointment. </span></p> <p><span style="color: black;">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><strong style="color: black;">Mentorship:</strong><span style="color: black;"> Applications must include at least one mentor who demonstrates experience in prostate cancer research and successful mentorship.</span></p> <p><span style="color: black;">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><strong style="color: black;">Researcher Development Plan:</strong><span style="color: black;"> Applications must include a research development plan articulating an individualized strategy for acquiring necessary skills, competence and expertise to complete the projects and foster the PI’s career development.</span></p> <p><br></p> <p><a href="https://cdmrp.health.mil/pubs/press/2026/pcrppreann" target="_blank">https://cdmrp.health.mil/pubs/press/2026/pcrppreann</a></p>

Defense Health Agency Contracting Activity - DHACA

<p><strong>Summary:</strong> The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Translational Research Award (TRA) supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Research must address at least one of the FY26 LCRP areas of emphasis.</p><p><br></p><p><strong>Distinctive Features:</strong> This funding mechanism intends to support a broad range of translational studies and allows application submission under: Funding Level 1 – Advanced/late-stage preclinical work or correlative studies; or Funding Level 2 – Pilot clinical trials of novel interventions.</p>

Defense Health Agency Contracting Activity - DHACA

<p><strong>Summary:</strong> The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Early Investigator Research Award (EIRA) supports prostate cancer research conducted by investigators in the early stages of their careers with guidance from an experienced mentor. All applications must address one of the <a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/PCRP/HT942526PCRPEIRA_for%20GO%20review.docx#Overarching_Challenges" target="_blank">FY26 PCRP Overarching Challenges</a>.<strong style="color: rgb(0, 176, 80);"><em> </em></strong></p> <p><br></p> <p><strong>Distinctive Features:</strong><strong style="color: red;"> </strong></p> <p><span style="color: black;">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><strong style="color: black;">Early-Career Investigator:</strong><span style="color: black;"> Serves as the principal investigator. Includes investigators possessing a doctoral degree or equivalent with fewer than three years of postdoctoral research experience at the application submission deadline, excluding clinical residency or clinical fellowship training.</span></p> <p><span style="color: black;">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><strong style="color: black;">Mentorship:</strong><span style="color: black;"> Applications must include at least one mentor who demonstrates experience in prostate cancer research and successful mentorship.</span></p> <p><span style="color: black;">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><strong style="color: black;">Researcher Development Plan: </strong><span style="color: black;">Applications must include a researcher development plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the Principal Investigator’s (PI’s) career development</span></p> <p><br></p> <p><br></p>

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Idea Development Award (IDA) supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from lung cancer. This mechanism promotes new ideas that are in the early stages of development and have the potential to yield impactful data and new avenues of investigation. Research must address at least one of the FY26 LCRP areas of emphasis.Distinctive Features: This FY26 LCRP IDA mechanism has a New Investigator category that is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators. Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of lung cancer.

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Translational Research Award (TRA) supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Research must address at least one of the FY26 LCRP areas of emphasis.Distinctive Features: This funding mechanism intends to support a broad range of translational studies and allows application submission under: Funding Level 1 Advanced/late-stage preclinical work or correlative studies; or Funding Level 2 Pilot clinical trials of novel interventions.

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Idea Development Award (IDA) supports new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. All applications must address one of the FY26 PCRP Overarching Challenges. Distinctive Features: New Investigator Category: In addition to established investigators, the FY26 PCRP Idea Development Award encourages research ideas from investigators in the early stages of their careers (i.e., within 10 years after completion of their terminal degree). Qualified new investigators must identify a collaborator(s) experienced in prostate cancer research. https://cdmrp.health.mil/pubs/press/2026/pcrppreann

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Data Science Award (DSA) supports research that develops or uses quantitative and analytical approaches, processes and/or systems to obtain knowledge and insight from large and/or complex sets of prostate cancer data in one or more of the following research areas: Analysis of clinically annotated datasets; analysis of -omics data; artificial intelligence and machine learning; bioinformatics; computational biology; digital pathology; epidemiology; and medical imaging. All applications must address one of the FY26 PCRP Overarching Challenges. Distinctive Features: This funding mechanism allows for multiple Principal Investigators (PIs). Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Patient-Centered Outcomes and Survivorship Award (PCOSA) promotes evidence-based and patient-centered approaches to improve health and lung cancer related outcomes and enhance the patient experience in defined populations. Research must address at least one of the FY26 LCRP areas of emphasis in the Health Outcomes and Survivorship category.Distinctive Features: This funding mechanism requires the research team to include an advocate who is a lung cancer patient/survivor or caregiver. This funding mechanism allows proposed projects to include translational or clinical research, including pilot clinical trials.

Defense Health Agency Contracting Activity - DHACA

<p><strong>Summary: </strong>The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Idea Development Award (IDA) supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from lung cancer. This mechanism promotes new ideas that are in the early stages of development and have the potential to yield impactful data and new avenues of investigation. Research must address at least one of the FY26 LCRP areas of emphasis.</p><p><br></p><p><strong>Distinctive Features:</strong> This FY26 LCRP IDA mechanism has a New Investigator category that is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators. Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of lung cancer.</p>

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Early Investigator Research Award (EIRA) supports prostate cancer research conducted by investigators in the early stages of their careers with guidance from an experienced mentor. All applications must address one of the FY26 PCRP Overarching Challenges. Distinctive Features: Early-Career Investigator: Serves as the principal investigator. Includes investigators possessing a doctoral degree or equivalent with fewer than three years of postdoctoral research experience at the application submission deadline, excluding clinical residency or clinical fellowship training. Mentorship: Applications must include at least one mentor who demonstrates experience in prostate cancer research and successful mentorship. Researcher Development Plan: Applications must include a researcher development plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the Principal Investigator s (PI s) career development

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Physician Research Award (PRA) Supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research. All applications must address one of the FY26 PCRP Overarching Challenges. Distinctive Features: Early-Career Clinician Investigator: Serves as the Principal Investigator (PI). Includes investigators with clinical duties in the last year of an accredited medical residency or medical fellowship program, or within five years of initiating a faculty appointment. Mentorship: Applications must include at least one mentor who demonstrates experience in prostate cancer research and successful mentorship. Researcher Development Plan: Applications must include a research development plan articulating an individualized strategy for acquiring necessary skills, competence and expertise to complete the projects and foster the PI s career development. https://cdmrp.health.mil/pubs/press/2026/pcrppreann

Defense Health Agency Contracting Activity - DHACA

<p><strong>Summary:</strong> The fiscal year 2026 (FY26) Vision Research Program (VRP) Mentored Clinical Research Award (MCRA) supports patient-oriented vision injury research conducted by highly motivated military or civilian clinicians in training. The MCRA may be used to support a standalone study of high impact to vision injury care or the generation of clinical research data in preparation for a more expansive study. Research must align with at least one of the <a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/VRP/HT942526VRPMCRA_GG.docx#FocusAreas" target="_blank">FY26 VRP Focus Areas</a>. The MCRA may<strong> not</strong> be used to support preclinical research or <a href="https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:~:text=or%20hardware%20procurement.-,Clinical%20Trial%3A,-As%20defined%20in" target="_blank">clinical trials</a>.</p> <p><strong>Distinctive Features: </strong></p> <p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Key personnel must include an established clinician or Ph.D. clinical scientist, who will serve as Principal Investigator (PI) and a clinician in training (e.g., a fellow, resident, junior clinician, clinician in a Ph.D. program), who will conduct the proposed research under mentorship of the PI, with support from supporting personnel as appropriate.</p> <p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The clinician in training should have sufficient time remaining in their training program to complete the research proposed under the MCRA.&nbsp;</p> <p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Scored<strong> </strong><a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/VRP/HT942526VRPMCRA_GG.docx#PeerReviewCriteria622" target="_blank"><strong>peer review criteria</strong></a> include Research Idea/Rationale, Research Strategy and Feasibility, Impact and Personnel.</p> <p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/VRP/HT942526VRPMCRA_GG.docx#Programmatic_Review" target="_blank"><strong>Programmatic review criteria</strong></a> include adherence to the intent of the MCRA, contribution to program portfolio, relative impact and relevance to military health.</p> <p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Applicants must submit <strong>documentation of Institutional Review Board (IRB)/Ethics Committee (EC) approval or exemption</strong> by <strong>January 1, 2027</strong>, in order for the MCRA application to be considered for funding.&nbsp;</p> <p><br></p> <p><a href="https://cdmrp.health.mil/pubs/press/2026/vrppreann" target="_blank">https://cdmrp.health.mil/pubs/press/2026/vrppreann</a></p>

Defense Health Agency Contracting Activity - DHACA

<p><strong>Summary:</strong> The fiscal year 2026 (FY26) Hearing Restoration Research Program (HRRP) Focused Research Award (FRA) supports promising research that accelerates drug discovery and therapeutic development for hearing restoration after military-relevant auditory system injury. The FRA may be used to support preclinical studies and/or clinical research. Research must align with at least one of the FY26 HRRP Focus Areas. The FRA cannot be used to support clinical trials, tinnitus research or vestibular research.</p><p><br></p><p><strong>Distinctive Features:</strong></p><p>• The FRA offers two Funding Levels to support research at different stages and the exploration/development of ideas of different maturity levels.</p><p>• Funding Level 2 includes a Partnering Principal Investigator (PI) Option (PPIO) for two PIs, an Initiating PI and a Partnering PI.</p><p>• Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact, and Personnel.</p><p>• Programmatic review criteria include adherence to the intent of the FRA, contribution to the HRRP portfolio, relative impact, and relevance to military health.</p>

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Hearing Restoration Research Program (HRRP) Focused Research Award (FRA) supports promising research that accelerates drug discovery and therapeutic development for hearing restoration after military-relevant auditory system injury. The FRA may be used to support preclinical studies and/or clinical research. Research must align with at least one of the FY26 HRRP Focus Areas. The FRA cannot be used to support clinical trials, tinnitus research or vestibular research.Distinctive Features: The FRA offers two Funding Levels to support research at different stages and the exploration/development of ideas of different maturity levels. Funding Level 2 includes a Partnering Principal Investigator (PI) Option (PPIO) for two PIs, an Initiating PI and a Partnering PI. Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact, and Personnel. Programmatic review criteria include adherence to the intent of the FRA, contribution to the HRRP portfolio, relative impact, and relevance to military health.

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Mentored Clinical Research Award (MCRA) supports patient-oriented vision injury research conducted by highly motivated military or civilian clinicians in training. The MCRA may be used to support a standalone study of high impact to vision injury care or the generation of clinical research data in preparation for a more expansive study. Research must align with at least one of the FY26 VRP Focus Areas. The MCRA may not be used to support preclinical research or clinical trials. Distinctive Features: Key personnel must include an established clinician or Ph.D. clinical scientist, who will serve as Principal Investigator (PI) and a clinician in training (e.g., a fellow, resident, junior clinician, clinician in a Ph.D. program), who will conduct the proposed research under mentorship of the PI, with support from supporting personnel as appropriate. The clinician in training should have sufficient time remaining in their training program to complete the research proposed under the MCRA. Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact and Personnel. Programmatic review criteria include adherence to the intent of the MCRA, contribution to program portfolio, relative impact and relevance to military health. Applicants must submit documentation of Institutional Review Board (IRB)/Ethics Committee (EC) approval or exemption by January 1, 2027, in order for the MCRA application to be considered for funding. https://cdmrp.health.mil/pubs/press/2026/vrppreann

Defense Health Agency Contracting Activity - DHACA

<p><strong>Summary:</strong> The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Neurofibromatosis Research Academy – Leadership Award (NFRALA) supports visionary, established neurofibromatosis (NF) investigators with documented history of neurofibromatosis funding, publications, strong mentorship and commitment to leadership to serve as Director and Deputy Director of the Neurofibromatosis Research Academy. The Academy Director and Deputy Director will execute a multi-institutional, interactive, virtual research academy that consists of scholars, who are early-career investigators, and their career guides, who serve as the scholars’ primary mentors.</p><p><br></p><p><strong>Distinctive Features:</strong></p><p>• Academy Director: Established NF investigators at or above the level of Associate Professor, or equivalent, at the full application submission deadline.</p><p>• Academy Deputy Director: Investigators at or above the level of Associate Professor, or equivalent, at the full application deadline and affiliated with a different institution than the Academy Director.</p><p>• Pilot Research Project: The Academy Director and Deputy Director will conduct one or more pilot research projects in collaboration with the academy scholars. Preliminary and/or published data relevant to NF and the proposed research project are encouraged but not required.</p><p><br></p>

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Neurofibromatosis Research Academy Leadership Award (NFRALA) supports visionary, established neurofibromatosis (NF) investigators with documented history of neurofibromatosis funding, publications, strong mentorship and commitment to leadership to serve as Director and Deputy Director of the Neurofibromatosis Research Academy. The Academy Director and Deputy Director will execute a multi-institutional, interactive, virtual research academy that consists of scholars, who are early-career investigators, and their career guides, who serve as the scholars primary mentors.Distinctive Features: Academy Director: Established NF investigators at or above the level of Associate Professor, or equivalent, at the full application submission deadline. Academy Deputy Director: Investigators at or above the level of Associate Professor, or equivalent, at the full application deadline and affiliated with a different institution than the Academy Director. Pilot Research Project: The Academy Director and Deputy Director will conduct one or more pilot research projects in collaboration with the academy scholars. Preliminary and/or published data relevant to NF and the proposed research project are encouraged but not required.